Medically reviewed by Dr Zeeshan Afzal (MBBS, General Practitioner) — Medical Content Reviewer, Welzo.
Written by: The Welzo Longevity Editorial Team | Last updated: July 2026
Evidence standard: Every dose and claim below is referenced to a named clinical trial, review or regulatory source. Where evidence is observational rather than interventional — which, for ergothioneine, is most of it — we say so explicitly. See our editorial policy.
Ergothioneine has the most seductive backstory in the longevity supplement category. It is also the clearest test of the standard we apply throughout our longevity supplements guide and across the anti-ageing and longevity supplements range: a compelling mechanism is not the same thing as proof.
On mechanism it outranks NMN; on trial evidence it is well behind — compare NMN benefits, side effects and dosage, the NMN supplements range and NMN Pro 1000, and see the longevity stack guide for where a compound like this belongs in a routine.
Your body cannot make ergothioneine. You obtain it entirely from food. And yet human physiology includes a dedicated, highly specific transporter whose apparent job is to capture it and concentrate it in exactly the tissues most exposed to oxidative stress. Evolution rarely builds bespoke machinery for molecules that do nothing.
That observation has led respected researchers to propose ergothioneine as a candidate "longevity vitamin". It has also led to a supplement category running considerably ahead of the trial evidence.
The short answer
Ergothioneine is a diet-derived antioxidant, found mainly in mushrooms, that humans absorb through a dedicated transporter (OCTN1/SLC22A4) and concentrate in tissues under oxidative stress [1]. In a Swedish cohort followed for over 21 years, higher blood ergothioneine was associated with lower risk of coronary disease, cardiovascular mortality and all-cause mortality [2]. Small interventional trials in older adults suggest possible benefits for cognition, memory and sleep, with no safety concerns up to 25 mg/day [3]. But there is no large outcome trial, and the biggest weakness is that ergothioneine was the metabolite most strongly linked to a healthy dietary pattern — so it may partly be measuring diet quality rather than causing benefit [2].
Table of contents
Ergothioneine is a sulphur-containing amino acid derivative — technically a thiol/thione compound — synthesised only by certain fungi and bacteria [1]. Humans and other animals cannot make it at all. Every molecule in your body arrived through your diet.
Chemically it behaves differently from familiar antioxidants. It is unusually stable, resistant to auto-oxidation, and its thione form has radical-scavenging properties that differ from those of ordinary thiol antioxidants [1]. It is also not rapidly metabolised or excreted in urine, and is present in many if not all human tissues and body fluids [1].
That last point matters. Most water-soluble antioxidants pass through you. Ergothioneine is retained — which is a meaningfully different pharmacological picture from the compounds assessed in longevity supplements that probably don't work.
This is the strongest thing anyone can say about ergothioneine, and it deserves to be stated carefully rather than overstated.
Humans express a specific, high-affinity transporter — OCTN1, encoded by the gene SLC22A4 and now also called the ergothioneine transporter — which actively takes up dietary ergothioneine and mediates its distribution into tissues and its reabsorption in the kidney [1]. Unlike most dietary antioxidants, which rely on passive diffusion, ergothioneine is actively pumped into cells.
More striking still is where. The transporter is not evenly distributed. It concentrates in tissues and cell types particularly exposed to oxidative stress and inflammation — bone marrow, developing red blood cells, monocytes and macrophages, and certain epithelial barriers — and there is evidence the body may raise OCTN1 levels at sites of tissue injury [1].
Building and expressing a dedicated transport protein costs metabolic energy. Organisms do not generally pay that cost to accumulate something useless. The reasonable inference is that ergothioneine does something worth retaining.
A transporter tells you the body values a molecule. It does not tell you that taking more of it produces a health benefit, and it certainly does not tell you how much more. Iron has sophisticated transport and storage machinery too, and supplementing iron in someone who is replete is harmful rather than helpful.
Blood ergothioneine does decline with age, and decreased levels have been observed in a range of diseases, which is suggestive [1]. It is not the same as demonstrating that raising levels reverses anything.
Calling ergothioneine an antioxidant undersells it slightly, because the proposed mechanisms are broader than radical scavenging:
Every item on that list is mechanistic or preclinical. They explain why researchers find the compound interesting; they do not substitute for outcome data.
Key takeaway: The transporter is genuinely remarkable and is the best argument for taking ergothioneine seriously as a research target. It is not, by itself, evidence that a supplement improves health outcomes — that requires trials, and the large ones have not been done.
Mushrooms are by a wide margin the richest dietary source, with oyster, shiitake and king oyster among the highest [1]. Smaller amounts appear in some beans, organ meats, oat bran, and grains grown in soils containing ergothioneine-producing fungi [1].
This creates an obvious and cheap first intervention: eat more mushrooms. They are inexpensive, widely available, and carry the rest of a mushroom's nutritional profile alongside the ergothioneine. Browse the Welzo mushroom supplements range if you want a concentrated route, and see our lion's mane UK guide for the wider category.
Ergothioneine is relatively heat-stable compared with many antioxidants, so normal cooking does not destroy it in the way it degrades vitamin C. Some may leach into cooking water, which is an argument for using the liquid rather than discarding it.
The headline finding comes from a Swedish cohort study with a median follow-up of 21.4 years, during which 603 participants developed cardiovascular disease, 362 developed diabetes and 843 died.
Ergothioneine was associated with a lower risk of coronary disease (hazard ratio 0.85 per one standard deviation increment, p = 0.01), lower cardiovascular mortality (HR 0.79, p = 0.002) and lower overall mortality [2]. Those are meaningful effect sizes over a long follow-up in a well-conducted cohort.
A 2025 review in Proceedings of the Nutrition Society summarised the wider picture: observational data consistently associate low blood ergothioneine with cognitive impairment, neurodegenerative disease, cardiovascular disorders, frailty and mortality [3].
Here the evidence thins considerably. The same review reports that interventional trials in older adults suggest ergothioneine supplementation may improve cognition, memory and sleep quality, and stabilise biomarkers of neurodegeneration, with no safety concerns identified at doses up to 25 mg/day [3].
Read that carefully. "Suggest", "may", and trials small enough that a review describes them collectively rather than by name. This is early-stage interventional evidence, not the kind of large randomised outcome trial that would settle the question.
It is worth being specific about what is missing, because "more research is needed" is a phrase that hides more than it reveals. To move ergothioneine from hypothesis to established, you would want a randomised, placebo-controlled trial of several thousand participants, running for years rather than months, measuring hard outcomes — cardiovascular events, cognitive decline on validated instruments, mortality — rather than biomarkers.
Nothing of that scale exists or is close to reporting. Given that ergothioneine is inexpensive, off-patent as a molecule and available from food, it is also not obvious who would fund one. That is a structural problem rather than a scientific verdict, but it does mean the evidence gap may persist for a long time.
This is the part that most ergothioneine content omits, and it is the single most important thing to understand before spending money.
In the Swedish study, ergothioneine was identified as the metabolite most strongly connected to a healthy dietary pattern [2]. It was measured precisely because it works well as a biomarker of eating a certain way.
So consider what a high blood ergothioneine level actually indicates. It indicates someone who eats mushrooms, and probably vegetables, and probably whole grains, and who is likely to differ from a low-ergothioneine person in dozens of ways the study could only partly adjust for. The association with lower mortality may reflect ergothioneine's biological activity — or it may reflect the diet that produced it.
Because we have watched it play out before. Resveratrol arrived with a compelling mechanism and epidemiological support from red wine consumption. When a study measured urinary resveratrol metabolites directly in 783 older adults over nine years, it found no association with inflammation, cardiovascular disease, cancer or mortality [4]. The molecule was not the active ingredient in the lifestyle.
Ergothioneine is in a better position than resveratrol was — the transporter evidence is genuinely stronger, and the observational data survived adjustment for conventional risk factors [2]. But the structure of the argument is similar enough to warrant caution. See does resveratrol actually work? for the full account.
Grouping every novel longevity compound under "unproven" loses useful information. Here is how ergothioneine actually compares:
| Compound | Mechanism | Human outcome trials | Honest status |
|---|---|---|---|
| Ergothioneine | Very strong — dedicated transporter, tissue targeting [1] | Small early trials only [3] | Compelling hypothesis, untested at scale |
| Urolithin A | Strong — mitophagy activation | Multiple RCTs; primary endpoint missed in one [5] | Promising, mixed, manufacturer-funded |
| NMN | Strong — raises NAD⁺ reliably | RCTs; no metabolic benefit in meta-analysis [6] | Biomarker moves, outcomes unclear |
| Resveratrol | Contested — sirtuin activation disputed | Prospective study found no mortality association [4] | Largely failed for healthy ageing |
Ergothioneine's position is unusual: the best mechanistic case and among the weakest interventional evidence. That is a compound worth watching rather than one worth building a routine around. Our wider assessment is in is NMN a scam?
Unusually for this category, there is a clear regulatory answer here rather than a marketing one — at least on the EU side.
L-ergothioneine is authorised as a novel food ingredient in the EU under Commission Implementing Regulation (EU) 2018/462, which sets maximum levels for food supplement use of 30 mg per day for adults and 20 mg per day for children over three [7]. The position in Great Britain is a separate question and should be checked directly with the Food Standards Agency before you buy: the UK legislation register records the UK version of that instrument as revoked [8], and novel food authorisations have been restructured in assimilated UK law since EU exit. Northern Ireland follows EU rules under the Windsor Framework.
The interventional trials summarised in the 2025 review used doses up to 25 mg/day and identified no safety concerns at that level [3].
| Question | Answer |
|---|---|
| Typical supplemental dose | 5–25 mg daily |
| Regulatory maximum (EU supplements) | 30 mg/day adults; 20 mg/day children over 3 [7] |
| Great Britain position | Check with the FSA — see note above [8] |
| Doses used in trials | Up to 25 mg/day, no safety concerns reported [3] |
| Duration before judging | Months — this is not an acute-effect compound |
| Form | L-ergothioneine, synthetic or fermentation-derived |
Note the contrast with most of this category: doses here are milligrams, not hundreds of milligrams. Anyone selling ergothioneine at dramatically higher amounts is exceeding the level EU regulators have assessed, which is a reason for caution rather than enthusiasm.
For most compounds in this category, the food route is impractical — you cannot eat enough pomegranate to reach a urolithin A trial dose. Ergothioneine is different. Mushrooms genuinely deliver meaningful amounts, they are cheap, and the observational data that makes ergothioneine interesting came from people eating food rather than taking capsules [2].
If you are not currently eating mushrooms regularly, starting is the intervention most consistent with the evidence — and it costs less than any supplement discussed on this site. Our cheap longevity stack takes the same food-first approach to omega-3.
Related guidance: third-party testing: what it means and what it doesn't and why supplements are expensive. Welzo's ranges sit in antioxidants, mushroom supplements and Welzo Ultra Purity.
Related comparisons: urolithin A vs NMN, spermidine vs NMN, fisetin vs quercetin, our NAD supplement guide and the hallmarks of ageing. For sequencing, see how to start longevity supplements and how long supplements take to work.
Speak to your GP or pharmacist before starting ergothioneine if you take prescription medication, have an existing medical condition, or are pregnant, breastfeeding or trying to conceive. Long-term safety data beyond the trial durations described above does not exist.
If your interest is driven by memory concerns, confusion or noticeable cognitive change, see a doctor rather than buying a supplement. Cognitive symptoms have many treatable causes — including thyroid dysfunction, B12 deficiency, depression, sleep apnoea and medication side effects — and none of them respond to antioxidants. A thyroid blood test, vitamin deficiency test or Full Body MOT Health Check is a far more useful first step, and persistent cognitive change warrants clinical assessment.
It is a sulphur-containing amino acid derivative made only by certain fungi and bacteria, which humans obtain entirely from diet — mainly mushrooms. It is absorbed by a dedicated transporter (OCTN1/SLC22A4) and concentrated in tissues exposed to oxidative stress, where it acts as a stable antioxidant and cytoprotective agent [1]. Whether supplementing it improves health outcomes has not been established in large trials.
That is a proposal, not a classification. Researchers have argued for the label on the basis that humans cannot synthesise it, have a dedicated transporter for it, retain it in tissues long-term, and show declining levels with age [1]. It is a reasonable hypothesis. It has not been demonstrated that supplementation extends healthspan or lifespan in humans.
In a Swedish cohort followed for a median 21.4 years, higher ergothioneine was associated with lower coronary disease risk (HR 0.85), cardiovascular mortality (HR 0.79) and overall mortality [2]. Observational data also link low levels to cognitive impairment, neurodegenerative disease, frailty and mortality [3]. Small interventional trials suggest possible cognition, memory and sleep benefits at up to 25 mg/day with no safety concerns [3]. There is no large randomised outcome trial.
Possibly, and this is the central weakness. In the Swedish study ergothioneine was the metabolite most strongly connected to a healthy dietary pattern [2] — meaning it works well as a marker of eating well. The association survived adjustment for conventional risk factors, which is reassuring, but residual confounding cannot be excluded. This is the same trap resveratrol fell into [4].
Typical supplemental doses are 5–25 mg daily. EU novel food authorisation sets a maximum of 30 mg per day for adults in food supplements, and 20 mg for children over three [7]. Interventional trials used up to 25 mg/day without safety concerns [3]. Doses far above the assessed level have not been evaluated and should be treated with caution.
Mushrooms by a wide margin — oyster, shiitake and king oyster are among the richest — with smaller amounts in some beans, organ meats, oat bran and grains grown in soils containing ergothioneine-producing fungi [1]. It is relatively heat-stable, so normal cooking does not destroy it, though some can leach into cooking liquid.
Unlike most compounds in this category, quite possibly yes. Mushrooms deliver meaningful amounts, and the epidemiology that makes ergothioneine interesting was generated in people eating food rather than taking supplements [2]. If you rarely eat mushrooms, adding them is the intervention most consistent with the evidence and costs less than any capsule.
The available evidence is reassuring at studied doses. Interventional trials identified no safety concerns up to 25 mg/day [3], and it holds EU novel food authorisation with defined maximum levels — a status many longevity compounds lack [7,9]. Long-term safety over years has not been established, and it has not been studied in pregnancy, breastfeeding or children.
L-ergothioneine is authorised as a novel food in the EU under Implementing Regulation (EU) 2018/462, with defined maximum supplement levels [7]. The Great Britain position is a separate matter — the UK legislation register records the UK version of that instrument as revoked [8], and novel food authorisations have been restructured in assimilated law since EU exit. Check the current status with the Food Standards Agency before purchasing, and note that Northern Ireland follows EU rules.
If you are choosing, take the better evidenced option first. Vitamin D has NHS population guidance behind it [10], creatine has one of the largest supplement evidence bases in existence [11,12], and both cost a fraction of a novel compound. Ergothioneine is a reasonable speculative addition once those are consistently covered — see the cheap longevity stack.
Medical disclaimer
This article is for general information and does not constitute medical or regulatory advice. Food supplements are not a substitute for a varied, balanced diet and a healthy lifestyle, and should not be used to treat or prevent disease. No supplement has been shown to extend human lifespan. Much of the evidence described here is observational and cannot demonstrate cause and effect. Regulatory positions on novel foods differ between Great Britain, Northern Ireland and the EU and change over time — check the current status with the Food Standards Agency before purchasing. Ergothioneine has not been studied in pregnancy, breastfeeding or children. Always consult a qualified healthcare professional before starting any new supplement, particularly if you take prescription medication or have an existing medical condition. Persistent cognitive symptoms warrant clinical assessment rather than self-supplementation. Reviewed for medical accuracy by Dr Zeeshan Afzal. See the full Welzo medical disclaimer.
All product photography in this article is owned by Welzo and served from the Welzo media library. Regulatory positions correct at the time of publication and subject to change.
Évalué Excellent par 26,523+ avis
Garantie de remboursement à 100%
Notre garantie de rétroaction garantit que vous recevez vos articles ou obtenez un remboursement complet.
